Forum

IPA.V - ImmunoPrecise Antibodies Ltd

Santé
#495

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products
27 Oct 202007:28 HE

CNW Group

IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary, Talem Therapeutics, entered into a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to leverage the unique strengths of both companies’ technologies in the creation of novel, therapeutic molecules.

By entering this early discovery collaboration with Twist, Talem will be expanding its diverse antibody pipeline by exploring IPA’s technology on a wider range of oncology targets, combining their expertise in a highly collaborative manner to discover novel antibody therapeutics. ImmunoPrecise will contribute targets of interest with relevant background data, and the genetic sequences encoding for lead antibodies against the selected targets. Twist Biopharma, a division of Twist Bioscience, will design synthetic antibody libraries based on the provided antibody repertoire sequences from immunized animals to discover optimized, humanized lead antibody candidates. The companies will then aim to jointly advance the programs through proof-of-concept and preclinical development and will collaborate on any commercial opportunities generated by these joint efforts which may result in milestones based on key preclinical, clinical and commercial milestones as well as royalties for any antibodies resulting from the collaboration.

« Our collaboration with Twist recognizes the potential of their well-established ability to create precision antibody discovery libraries, enabling us to further expedite our pre-clinical development through collaboration, » said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. « We look forward to working closely with Twist to pioneer the discovery and development of new, cutting-edge cancer treatments. »

2 « J'aime »
#496

U.S. agrees to pay Eli Lilly $375 million for 300,000 doses of coronavirus antibody drug

The agreement with the U.S. came days after the company said a trial of the drug failed to show a benefit in hospitalized patients. The company said it is confident the drug is helpful to those earlier in the course of Covid-19.

1 « J'aime »
#497

Paul buying again in the public market

image
image1013×229 53.4 KB

1 « J'aime »
#498
1 « J'aime »
#499

Salut Frederick! Je suis curieux de savoir quelle est ta lecture de la baisse constante d’IPA ce dernier mois ? Rien n’à changé sur le fond, mais peut-être as-tu une opinion pour nous éclairer, toi qui est proche de la société.

#500

Dr Brolo fera une présentation le 6 novembre lors de la 4th Annual Biomedical Engineering and Health Science Showcase. Je suppose que nous aurons plus de détails sur le test de salive.

Alexandre Brolo , UVic Professor. Presenting: COVID Diagnostic Project with ImmunoPrecise Antibodies

1 « J'aime »
#501

De la prise de profit à la retraite des Beecroft. Il y aura toujours cette méfiance face à un deal de Vancouver jusqu’au moment où la compagnie changera de marché soit le NASDAQ et le volume est en majorité généré par les spéculateurs. Ceci étant dit j’ai des fonds institutionnels US qui on commencé une accumulation.

1 « J'aime »
#502

ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership
03 Nov 202007:30 HE

CNW Group

IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced a research partnership with Mila, a world-renowned research institute dedicated to artificial intelligence (AI) development and focused on deep learning optimization for AI and machine language learning.

ImmunoPrecise and Mila will collaborate on research and talent development initiatives as the Company continues to advance next generation innovation in therapeutics. The collaboration will leverage data and artificial intelligence to transform how novel therapeutics are discovered and developed. Founded by Professor Yoshua Bengio, co-recipient of the 2018 Turing Prize, the Mila Institute is recognized worldwide for its significant contributions in the field of deep learning and has established itself in the fields of language modeling, machine translation, object recognition, and generative design.

« This partnership opens up an exciting opportunity for AI to tap into unexplored datasets generated by ImmunoPrecise’s effective and high-throughput therapeutic antibody discovery platforms, to contribute to the design of new therapeutics against life-threatening diseases that challenge humanity, » stated Mila Founder, Yoshua Bengio.

« This partnership reflects IPA’s deep-seeded commitment to innovation, » said Dr. Jennifer Bath, CEO of ImmunoPrecise. « Combining our efforts with the world-renowned talent at Mila catalyzes our advancements beyond the traditional life science model, as we continue to embrace the future of therapeutic discovery to accelerate the commercialization of life saving therapeutics. »

This partnership comes on the heels of ImmunoPrecise engaging LaPorte Expert Conseil Inc., with whom the Company has recently completed a feasibility study for the design of a Good Manufacturing Practices (GMP) facility. ImmunoPrecise’s partnerships with Mila and LaPorte were facilitated by Montréal International, an economic promotion agency focused on the growth of Greater Montréal, as a part of Montréal International’s ongoing efforts to support ImmunoPrecise in leveraging unique life science and technology partnerships.

About Mila Founded in 1993 by Professor Yoshua Bengio of the Université de Montréal, Mila is a research institute in artificial intelligence which rallies 500 researchers specializing in the field of deep learning. Based in Montréal, Mila’s mission is to be a global pole for scientific advances that inspires innovation and the development of AI for the benefit of all.

Since 2017, Mila is the result of a partnership between the Université de Montréal and McGill University, closely linked with Polytechnique Montréal and HEC Montréal, and gathers in its offices a community of professors, students, industrial partners and startups working in AI, making the institute the world’s largest academic research center in deep learning.

Mila, a non-profit organization, is recognized globally for its significant contributions to the field of deep learning, Mila has distinguished itself in the areas of language modelling, machine translation, object recognition and generative models.

#503

L’Institut québécois d’intelligence artificielle (MILA) dévoile une application de traçage de la COVID-19 qui se nomme COVI, qui prétend donner le pouvoir de se protéger du coronavirus et de limiter sa propagation.

L’application intégrée aux téléphones intelligents permettra de recueillir et de colliger en réseau des informations sur d’autres personnes, ce qui, croit-on, aidera à calculer la probabilité d’être infecté par le coronavirus.

L’application n’avait pas été retenue par le gouvernement fédéral. Par contre, est-ce que ce pourrait être un partenariat qui permettra d’intégrer à l’application COVI le test de salive créé par Dr Brolo?

1 « J'aime »
#504
#506

C’est une excellent idée. Je fais suivre! :snowboarder:

#507
1 « J'aime »
#508

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

NEWS PROVIDED BY

ImmunoPrecise Antibodies Ltd.

Nov 04, 2020, 19:08 ET

VICTORIA, BC, Nov. 4, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the " Company " or " IPA « ) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it intends to complete a consolidation of its issued and outstanding common shares ( » Common Shares ") on the basis of one (1) new Common Share for every five (5) Common Shares presently issued and outstanding (the " Consolidation "). Completion of the Consolidation remains subject to the approval of the TSX Venture Exchange (the " TSXV ").

Pursuant to the articles of the Company, the Board of Directors (" Board « ) of the Company has approved the Consolidation by way of Board resolutions. The Consolidation is being conducted to meet one of the listing rules of the Nasdaq Capital Market ( » Nasdaq "), which require the Company to maintain a minimum bid price per Common Share, in connection with a potential listing of the Company’s Common Shares on Nasdaq. The Board believes the Consolidation and a Nasdaq listing will enable the Company to gain increased liquidity and trading volume and broaden the Company’s investor base.

Upon receipt of TSXV approval of the Consolidation, IPA will provide additional details regarding a new CUSIP number for its Common Shares to distinguish between the pre- and post-consolidated Common Shares. IPA’s name and trading symbol will remain unchanged. Following the completion of the Consolidation, the Company will have approximately 16,700,000 Common Shares issued and outstanding.

Upon completion of the Consolidation, letters of transmittal describing the details of the Consolidation and the process by which shareholders obtain actual share certificates representing the consolidated Common Shares will be mailed to IPA’s registered shareholders. Registered shareholders will also be able to obtain copies of the letter of transmittal by contacting their brokers or other intermediary, or IPA’s transfer agent, Computershare Trust Company of Canada.

Shareholders who hold their shares through their broker or other intermediary and do not have actual share certificates registered in their name will not be required to complete and return a letter of transmittal. Any pre-consolidation Common Shares owned by such shareholders will automatically be adjusted as a result of the Consolidation to reflect the applicable number of post-consolidation Common Shares owned by them and no further action is required to be taken by such shareholders. If, as a result of the Consolidation, a shareholder becomes entitled to a fractional share, such fractions will be rounded to the nearest whole Common Share.

1 « J'aime »
#509

Je ne suis pas surpris du 5 vs 1. Lors de l’entrevue avec smallcapdiscoveries, ils avaient dit que certaines institutions ne pouvaient acheter si le prix de l’action était en bas de 10$. Par conséquent, ils s’assurent de pouvoir aller chercher plus d’investisseurs.

1 « J'aime »
#510

En autant que le prix reste stable! Les investisseurs détestent les rollback… Souhaitons que tout se passe bien

1 « J'aime »
#511

Selon mon expérience, ça dépend beaucoup du contexte. Une compagnie en difficulté financière qui fait un rollback quand le titre est 0,01$ pour pouvoir lever du financement par la suite, ça peut être mal reçu des investisseurs. Mais même là ce n’est pas toujours le cas (regarde Mediavalet après son rollback en octobre 2019).

À l’inverse, une entreprise qui fait un rollback pour aller se lister sur le NASDAQ et qui a des catalyseurs / développements fondamentaux positifs à l’horizon, ça a de très bonnes chances de bien se passer selon moi. Mais bon, je ne peux pas prédire l’avenir. On verra bien!

8 « J'aime »
#512

ImmunoPrecise_PRELIMINARY SHORT FORM BASE SHELF PROSPECTUS.pdf (420,7 Ko)

Bonne Lecture!!

1 « J'aime »
#513

Est-ce qu’il demeure sur le TSX venture même s’il va être listé sur le Nasdaq?

#514

Oui jusqu’à ce qu’il y ait une majorité d’actionnaires américains, à ce moment IPA devra se conformer aux normes de divulgations du NASDAQ et il sera inutile de rester sur le TSXV.

1 « J'aime »
#515

Un rapport sur Value Investor. Ça date un peu mais donne une bonne lecture générale de la compagnie.

1fqed2p-IPA.pdf (789,2 Ko)